Eiger prices $43.4M follow-on

Orphan disease company Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) raised $43.5 million through the sale of 4.3 million shares at $10.35 in a follow-on underwritten by BTIG. The price is a 13% discount to the company's close of $11.89 on Oct. 19, before Eiger proposed the offering.

Eiger plans to use the proceeds to fund a lonafarnib Phase III trial of lonafarnib to treat HDV infection. The company intends to submit an NDA to FDA next year for lonafarnib to treat Hutchinson-Gilford progeria syndrome, an ultra-rare premature aging disease (see "Eiger to Seek FDA Approval of Progeria Therapy"). ...